Cargando…

Development of a Multiplex Autoantibody Test for Detection of Lung Cancer

Lung cancer is the leading cause of cancer-related deaths for both men and women. Early diagnosis of lung cancer has a 5-year survival rate of 48.8%, however, nearly 35% of stage I patients relapses after surgical resection, thus portending a poor prognosis. Therefore, detecting lung cancer in early...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Jing, Wang, Wenzhe, Meng, Wen, Ding, Mingjian, Ma, Shenglin, Wang, Xiaoju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3995760/
https://www.ncbi.nlm.nih.gov/pubmed/24755629
http://dx.doi.org/10.1371/journal.pone.0095444
_version_ 1782312930554937344
author Jia, Jing
Wang, Wenzhe
Meng, Wen
Ding, Mingjian
Ma, Shenglin
Wang, Xiaoju
author_facet Jia, Jing
Wang, Wenzhe
Meng, Wen
Ding, Mingjian
Ma, Shenglin
Wang, Xiaoju
author_sort Jia, Jing
collection PubMed
description Lung cancer is the leading cause of cancer-related deaths for both men and women. Early diagnosis of lung cancer has a 5-year survival rate of 48.8%, however, nearly 35% of stage I patients relapses after surgical resection, thus portending a poor prognosis. Therefore, detecting lung cancer in early stage and further identifying the high-risk patients would allow the opportunity to provide adjuvant therapy and possibly increase survival. There is considerable evidence that the immune system produces an autoantibody response to neoplastic cells. The detection of such autoantibodies has been shown to have diagnostic and prognostic value. Here we took advantage of the high-throughput Luminex technique to multiplex a total of 14 tumor-associated autoantigens to detect the autoantibody from the patients sera. The 14 antigens were expressed by in vitro transcription/translation system with HaloTag at N-terminus. The fusion proteins were then covalently immobilized onto the Luminex microspheres conjugated by the halo-link ligand, thus eliminating the protein purification procedure. Sera samples from cancer patients and healthy controls were interacted with the microsphere-antigen complex to measure the autoantibodies. We have developed a quick multiplex detection system for measuring autoantibody signature from patient sera with minimal cross-reaction. A panel of seven autoantibody biomarkers has generated an AUC>80% in distinguishing the lung cancers from healthy controls. This study is the first report by combining Luminex platform and HaloTag technology to detect humoral immune response in cancer patients. Due to the flexibility of the Luminex technology, this approach can be applied to others conditions such as infectious, neurological, and metabolic diseases. One can envision that this multiplex Luminex system as well as the panel of seven biomarkers could be used to screen the high-risk population with subsequent CT test based on the blood test result.
format Online
Article
Text
id pubmed-3995760
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-39957602014-04-25 Development of a Multiplex Autoantibody Test for Detection of Lung Cancer Jia, Jing Wang, Wenzhe Meng, Wen Ding, Mingjian Ma, Shenglin Wang, Xiaoju PLoS One Research Article Lung cancer is the leading cause of cancer-related deaths for both men and women. Early diagnosis of lung cancer has a 5-year survival rate of 48.8%, however, nearly 35% of stage I patients relapses after surgical resection, thus portending a poor prognosis. Therefore, detecting lung cancer in early stage and further identifying the high-risk patients would allow the opportunity to provide adjuvant therapy and possibly increase survival. There is considerable evidence that the immune system produces an autoantibody response to neoplastic cells. The detection of such autoantibodies has been shown to have diagnostic and prognostic value. Here we took advantage of the high-throughput Luminex technique to multiplex a total of 14 tumor-associated autoantigens to detect the autoantibody from the patients sera. The 14 antigens were expressed by in vitro transcription/translation system with HaloTag at N-terminus. The fusion proteins were then covalently immobilized onto the Luminex microspheres conjugated by the halo-link ligand, thus eliminating the protein purification procedure. Sera samples from cancer patients and healthy controls were interacted with the microsphere-antigen complex to measure the autoantibodies. We have developed a quick multiplex detection system for measuring autoantibody signature from patient sera with minimal cross-reaction. A panel of seven autoantibody biomarkers has generated an AUC>80% in distinguishing the lung cancers from healthy controls. This study is the first report by combining Luminex platform and HaloTag technology to detect humoral immune response in cancer patients. Due to the flexibility of the Luminex technology, this approach can be applied to others conditions such as infectious, neurological, and metabolic diseases. One can envision that this multiplex Luminex system as well as the panel of seven biomarkers could be used to screen the high-risk population with subsequent CT test based on the blood test result. Public Library of Science 2014-04-22 /pmc/articles/PMC3995760/ /pubmed/24755629 http://dx.doi.org/10.1371/journal.pone.0095444 Text en © 2014 Jia et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Jia, Jing
Wang, Wenzhe
Meng, Wen
Ding, Mingjian
Ma, Shenglin
Wang, Xiaoju
Development of a Multiplex Autoantibody Test for Detection of Lung Cancer
title Development of a Multiplex Autoantibody Test for Detection of Lung Cancer
title_full Development of a Multiplex Autoantibody Test for Detection of Lung Cancer
title_fullStr Development of a Multiplex Autoantibody Test for Detection of Lung Cancer
title_full_unstemmed Development of a Multiplex Autoantibody Test for Detection of Lung Cancer
title_short Development of a Multiplex Autoantibody Test for Detection of Lung Cancer
title_sort development of a multiplex autoantibody test for detection of lung cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3995760/
https://www.ncbi.nlm.nih.gov/pubmed/24755629
http://dx.doi.org/10.1371/journal.pone.0095444
work_keys_str_mv AT jiajing developmentofamultiplexautoantibodytestfordetectionoflungcancer
AT wangwenzhe developmentofamultiplexautoantibodytestfordetectionoflungcancer
AT mengwen developmentofamultiplexautoantibodytestfordetectionoflungcancer
AT dingmingjian developmentofamultiplexautoantibodytestfordetectionoflungcancer
AT mashenglin developmentofamultiplexautoantibodytestfordetectionoflungcancer
AT wangxiaoju developmentofamultiplexautoantibodytestfordetectionoflungcancer